Gilead Didn't Pay Teva In HIV Drug IP Deal, Economist Says

By Bonnie Eslinger · June 26, 2023, 9:52 PM EDT

An economics expert for Gilead and Teva, testifying Monday in a federal antitrust trial over claims the pharmaceutical giants struck an illegal "pay for delay" patent deal over two HIV medications,...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login

Related Sections

Case Information

Case Title

In re HIV Antitrust Litigation

Case Number

3:19-cv-02573

Court

California Northern

Nature of Suit

Anti-Trust

Date Filed

May 14, 2019